Equillium acquires Bioniz Therapeutics to expand immunomodulatory drug pipeline
Equillium, a Nasdaq-listed biotech company, has acquired Bioniz Therapeutics in a deal worth up to around $329 million, in a move to considerably expand its ... Read More
Sanofi signs $1.45bn deal to acquire Kymab, expanding its immune-therapy pipeline
In a significant move to bolster its immuno-oncology and immune-mediated disease portfolio, Sanofi has acquired Kymab, a UK-based clinical-stage biopharma company, in a deal valued ... Read More